These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 23228038)

  • 1. Clarifying off-target effects for torcetrapib using network pharmacology and reverse docking approach.
    Fan S; Geng Q; Pan Z; Li X; Tie L; Pan Y; Li X
    BMC Syst Biol; 2012 Dec; 6():152. PubMed ID: 23228038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
    Johns DG; Duffy J; Fisher T; Hubbard BK; Forrest MJ
    Drugs; 2012 Mar; 72(4):491-507. PubMed ID: 22356288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of torcetrapib in patients at high risk for coronary events.
    Barter PJ; Caulfield M; Eriksson M; Grundy SM; Kastelein JJ; Komajda M; Lopez-Sendon J; Mosca L; Tardif JC; Waters DD; Shear CL; Revkin JH; Buhr KA; Fisher MR; Tall AR; Brewer B;
    N Engl J Med; 2007 Nov; 357(21):2109-22. PubMed ID: 17984165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.
    Vergeer M; Bots ML; van Leuven SI; Basart DC; Sijbrands EJ; Evans GW; Grobbee DE; Visseren FL; Stalenhoef AF; Stroes ES; Kastelein JJ
    Circulation; 2008 Dec; 118(24):2515-22. PubMed ID: 19029469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition.
    Hu X; Dietz JD; Xia C; Knight DR; Loging WT; Smith AH; Yuan H; Perry DA; Keiser J
    Endocrinology; 2009 May; 150(5):2211-9. PubMed ID: 19164467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver.
    Gauthier A; Lau P; Zha X; Milne R; McPherson R
    Arterioscler Thromb Vasc Biol; 2005 Oct; 25(10):2177-84. PubMed ID: 16123327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Network pharmacology-based strategy to investigate pharmacological mechanisms of Tinospora sinensis for treatment of Alzheimer's disease.
    Zhou F; He K; Guan Y; Yang X; Chen Y; Sun M; Qiu X; Yan F; Huang H; Yao L; Liu B; Huang L
    J Ethnopharmacol; 2020 Sep; 259():112940. PubMed ID: 32389853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation).
    Nicholls SJ; Tuzcu EM; Brennan DM; Tardif JC; Nissen SE
    Circulation; 2008 Dec; 118(24):2506-14. PubMed ID: 19029466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors.
    Xie L; Li J; Xie L; Bourne PE
    PLoS Comput Biol; 2009 May; 5(5):e1000387. PubMed ID: 19436720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.
    Davidson MH; McKenney JM; Shear CL; Revkin JH
    J Am Coll Cardiol; 2006 Nov; 48(9):1774-81. PubMed ID: 17084249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility.
    Kalgutkar AS; Frederick KS; Hatch HL; Ambler CM; Perry DA; Garigipati RS; Chang GC; Lefker BA; Clark RW; Morehouse LA; Francone O; Hu X
    Xenobiotica; 2014 Jul; 44(7):591-605. PubMed ID: 24380613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
    McKenney JM; Davidson MH; Shear CL; Revkin JH
    J Am Coll Cardiol; 2006 Nov; 48(9):1782-90. PubMed ID: 17084250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels.
    Clerc RG; Stauffer A; Weibel F; Hainaut E; Perez A; Hoflack JC; Bénardeau A; Pflieger P; Garriz JM; Funder JW; Capponi AM; Niesor EJ
    J Hypertens; 2010 Aug; 28(8):1676-86. PubMed ID: 20498617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
    Barter P
    Am J Cardiol; 2009 Nov; 104(10 Suppl):10E-5E. PubMed ID: 19895939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of torcetrapib on the progression of coronary atherosclerosis.
    Nissen SE; Tardif JC; Nicholls SJ; Revkin JH; Shear CL; Duggan WT; Ruzyllo W; Bachinsky WB; Lasala GP; Tuzcu EM;
    N Engl J Med; 2007 Mar; 356(13):1304-16. PubMed ID: 17387129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
    Brousseau ME; Schaefer EJ; Wolfe ML; Bloedon LT; Digenio AG; Clark RW; Mancuso JP; Rader DJ
    N Engl J Med; 2004 Apr; 350(15):1505-15. PubMed ID: 15071125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spotlight on HDL-raising therapies: insights from the torcetrapib trials.
    Kontush A; Guérin M; Chapman MJ
    Nat Clin Pract Cardiovasc Med; 2008 Jun; 5(6):329-36. PubMed ID: 18431367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone.
    Forrest MJ; Bloomfield D; Briscoe RJ; Brown PN; Cumiskey AM; Ehrhart J; Hershey JC; Keller WJ; Ma X; McPherson HE; Messina E; Peterson LB; Sharif-Rodriguez W; Siegl PK; Sinclair PJ; Sparrow CP; Stevenson AS; Sun SY; Tsai C; Vargas H; Walker M; West SH; White V; Woltmann RF
    Br J Pharmacol; 2008 Aug; 154(7):1465-73. PubMed ID: 18536749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition.
    Connelly MA; Parry TJ; Giardino EC; Huang Z; Cheung WM; Chen C; Cools F; Van der Linde H; Gallacher DJ; Kuo GH; Sarich TC; Demarest KT; Damiano BP
    J Cardiovasc Pharmacol; 2010 May; 55(5):459-68. PubMed ID: 20051879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.
    Williams SA; Murthy AC; DeLisle RK; Hyde C; Malarstig A; Ostroff R; Weiss SJ; Segal MR; Ganz P
    Circulation; 2018 Mar; 137(10):999-1010. PubMed ID: 28974520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.